HEREDITARY ANGIOEDEMA IN LATIN AMERICA: ARE WE IMPROVING?

Mexico Costa Rica El Salvador Colombia Panama Ecuador Peru Brazil Bolivia Paraguay Chile Uruguay Argentina

We have more patients and more countries with HAE diagnosed Country 2013 2017 Argentina 219 428 Bolivia 1 Brazil 572 814 Chile 4 51 Colombia 20 60 Costa Rica 10 El Salvador 2 5 Ecuador Mexico 34 224 Panama 9 Paraguay Peru 11 Uruguay 13

We have more patients and more countries with HAE identified Country 2013 2017 Argentina 219 428 Bolivia 1 Brazil 572 814 Chile 4 51 Colombia 20 60 Costa Rica 10 El Salvador 2 5 Ecuador Mexico 34 224 Panama 9 Paraguay Peru 11 Uruguay 13 866

We have more patients and more countries with HAE diagnosed Country 2013 2017 Argentina 219 428 Bolivia 1 Brazil 572 814 Chile 4 51 Colombia 20 60 Costa Rica 10 El Salvador 2 5 Ecuador Mexico 34 224 Panama 9 Paraguay Peru 11 Uruguay 13 1614

Ratio Female : Male was 1.9

Female HAE patients predominate except in Peru

Less than 5 % of patients have been diagnosed with HAE type 2

The acess to functional assays is still restricted for latin america

HAE WITH NL C1-INH IN LATAM Mexico Costa Rica El Salvador Colombia Panama Ecuador Peru Brazil Bolivia Paraguay Chile Uruguay Argentina

Therapy Country/ Drug Androgen Plasmin Inhib Plasma pdC1Inh Icatibant Argentina Bolivia Brazil Chile Colombia Costa Rica El Salvador Ecuador Mexico Panama Paraguay Peru Uruguay

J Fabiani, AS Grumach, SOR Valle, M Olivares, S Nieto, EH Landeros, A Ginaca; L Bezrodnik, E Nievas, M Oleastro, OM Barrera, AM Gallardo, A King, JR Galindo, MJO Carabantes, T Craig, MM Alfonso, C Montenegro

PROGRESS LATAM Population 569 millions of inhabitants 11.380 patients 866 (7.6%) identified LATAM Population 635 millions of inhabitants 12.700 patients 1614 (12.7%) identified

CONCLUSIONS The number of Latin American countries with reported cases of Hereditary Angioedema improved but the patients’ identification is still below than expected. Diagnosis of HAE type II is restricted in most of the countries. HAE with normal C1-INH has been detected in Brazil, Mexico, Argentina, Chile and Colombia but F12 mutation has been published in Brazil only.

CONCLUSIONS Brazil, Mexico, Argentina and Colombia have drugs for attacks launched. Even fresh frozen plasma (FFP) is not available in few countries. Nadroparine has been used in Mexico and Uruguay. Prophylactic therapy is not commercially available in Bolivia, Paraguay and Peru. Educative programs have been running in most of the countries although access to therapy is profoundly restricted.

Improved but not finished

Acknowledgements Argentina Bolivia Brazil Chile Colombia Costa Rica Adrian Maldonado (La Rioja) Daniel Osvaldo Vazquez Dario Joszviak (Santa Fe) Griselda Moreno (Catamarca) Jose Fabiani (Buenos Aires) Monica Marocco (Cordoba) Natalia Fili (Salta) Ricardo Zwiener (Catamarca) Argentinian Society of HAE patients Bolivia Luiz Fernando Landivar-Salinas Brazil GEBRAEH Brazilian Association of HAE Patients (ABRANGHE) Chile Ana Maria Gallardo-Olivos Masumi Grau Pablo Raby Rolando Campilay Colombia Carlos Olmos Margarita Olivares Costa Rica Mario Martinez Alfonso El Salvador Marlon Ochoa Joel Carabantes Equador Edison Zapata-Venegas Mexico Maria E Hernandez-Landeros Sandra Nieto Mexican Association of HAE patients Panama Olga Barrera Del Pino Paraguai Manuel Ratti Peru Julian Rodriguez-Galindo Oscar Calderón-Llosa Uruguai Maria Rosario Grauert

Inmaculada Martinez-Saguer Konrad Bork Marco Cicardi